ArticleDiscover oncology2025

A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting.

Fenglin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.